Sulfamethoxypyridazine

Sulfamethoxypyridazine

SCHEMBL93617

COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Sulfamethoxypyridazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
CYP2C19 P33261 2/20 1.00
ALDH1A1 P00352 4/20 0.68
KDM4E B2RXH2 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
HTR6 P50406 3/20 0.63
CYP3A4 P08684 1/20 0.63
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
MAPT P10636 1/20 0.51
ADRA1A P35348 1/20 0.51
EPHX2 P34913 1/20 0.51
PDE4A P27815 1/20 0.50
AGO2 Q9UKV8 1/20 0.50
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfamethoxypyridazine SCHEMBL10777132 1.00 LMNA (1.00) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
Sulfamethoxypyridazine SCHEMBL29360723 1.00 LMNA (1.00) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
Sulfamethoxypyridazine SCHEMBL29377020 1.00 LMNA (1.00) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
Sulfamethoxypyridazine SCHEMBL11516439 0.98 LMNA (0.97) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
Sulfamethoxypyridazine SCHEMBL27484423 0.98 LMNA (0.97) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
Sulfamethoxypyridazine SCHEMBL11026411 0.97 LMNA (0.94) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
Sulfamethoxypyridazine SCHEMBL28086651 0.88 LMNA (0.77) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
SCHEMBL2490831 0.86 LMNA (0.75) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
SCHEMBL29471766 0.86 LMNA (0.75) LMNASMN1; SMN2CYP2C19ALDH1A1KDM4E
SCHEMBL12462719 0.84 LMNA (0.75) LMNASMN1; SMN2CYP2C19ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4498 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091119-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA CELLIS AG (CH) 2026-04-02 US claimed
EP-4680248-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM Topelia Aust Limited (ACN 652 771 670) (AU) 2026-01-21 EP claimed
EP-4448107-B1 DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF FACULDADE DE FARMACIA DA UNIV DE LISBOA (PT) 2025-11-05 EP claimed
EP-4637829-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER Cellis Sp. z o.o. ([Ltd.] (PL) 2025-10-29 EP claimed
US-12433869-B2 Preventing and treating malaria Shine, Ian Basil (US) 2025-10-07 US claimed
EP-4587062-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA Cellis AG (CH) 2025-07-23 EP claimed
US-20250160275-A1 COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-05-22 US claimed
EP-4552693-A2 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF Sustain Holdings, LLC (US) 2025-05-14 EP claimed
EP-4178637-B1 MEDICAL DEVICES HAVING ANTI-MICROBIAL PROPERTIES AND METHODS FOR MAKING THE SAME HOLLISTER INC (US) 2025-05-14 EP claimed
EP-4552661-A2 MEDICAL DEVICES HAVING ANTI-MICROBIAL PROPERTIES AND METHODS FOR MAKING THE SAME Hollister Incorporated (US) 2025-05-14 EP claimed
EP-0255100-A2 Use of trimetrexate and its salts for the preparation of pharmaceutical compositions for treating infections of the mycobacterium-avium-intracellulare complex WARNER-LAMBERT COMPANY (US) 1988-02-03 EP claimed
US-4661340-A Quail egg based stabilized foam compositions for cosmetic purposes INTERKEMIA VEGYIPARI GAZDASAGI TARSASAG (HU) 1987-04-28 US claimed
US-4599416-A Process for the preparation of aqueous solutions of potentiated sulfonamides HOFFMANN-LA ROCHE INC. (US) 1986-07-08 US claimed
US-4532245-A Pharmaceutical compositions HOFFMANN-LA ROCHE INC. (US) 1985-07-30 US claimed
US-4315931-A MICROBIOCIDES, INFECTIOUS DISEASES BASF AKTIENGESELLSCHAFT (DE) 1982-02-16 US claimed
US-4169763-A OF A CORYNEBACTERIA RESISTANT TO ASPARTIC ACID ANALOGS AND SULFA DRUGS KYOWA HAKKO KOGYO CO., LTD. (JP) 1979-10-02 US claimed
US-4164559-A CARRIER MEMBRANE FOR OPHTHALMIC MEDICATION CORNELL RESEARCH FOUNDATION, INC. (US) 1979-08-14 US claimed
US-4082842-A SULFONYLUREA-TYPE HYPOGLYCEMIC, ASCORBIC ACID, SULFAMETHOXYPYRIDAZINE NAHLE ARMANDO 1978-04-04 US claimed
US-3978201-A BASE FOR OPHTHALMOLOGICAL MEDICINAL PREPARATION ON OPTHALMOLOGICAL MEDICINAL FILM KHROMOV GENNADY LVOVICH 1976-08-31 US claimed
US-3935303-A Base for ophthalmological medicinal preparations and on ophthalmological medicinal film KHROMOV GENNADY LVOVICH 1976-01-27 US claimed